HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

William R Hiatt Selected Research

Ecraprost

5/2007Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes.
4/2006Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


William R Hiatt Research Topics

Disease

92Peripheral Arterial Disease
01/2022 - 01/2002
31Myocardial Infarction
10/2021 - 01/2002
21Ischemia
01/2022 - 09/2004
20Hemorrhage
10/2022 - 02/2008
19Intermittent Claudication
06/2017 - 01/2002
16Ischemic Stroke
10/2021 - 01/2018
16Stroke (Strokes)
11/2020 - 01/2002
11Chronic Limb-Threatening Ischemia
01/2021 - 03/2003
8Diabetes Mellitus
01/2022 - 05/2008
6Venous Thromboembolism
10/2022 - 01/2016
6Thrombosis (Thrombus)
10/2021 - 01/2003
6Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 07/2011
6Atrial Fibrillation
01/2021 - 06/2008
6Atherosclerosis
10/2019 - 01/2002
5Coronary Artery Disease (Coronary Atherosclerosis)
10/2021 - 04/2003
5Hypertension (High Blood Pressure)
01/2021 - 01/2002
5Dyslipidemias (Dyslipidemia)
12/2018 - 01/2002
4Heart Failure
12/2018 - 01/2002
3Type 2 Diabetes Mellitus (MODY)
01/2019 - 01/2013
3Vascular Diseases (Vascular Disease)
01/2018 - 01/2003
3Acute Coronary Syndrome
01/2018 - 06/2015
3Coronary Disease (Coronary Heart Disease)
01/2018 - 12/2005
3Venous Thrombosis (Deep-Vein Thrombosis)
01/2016 - 01/2003
3Inflammation (Inflammations)
04/2015 - 11/2007
3Arterial Occlusive Diseases (Arterial Occlusive Disease)
05/2008 - 07/2002
2Thromboembolism
12/2021 - 01/2016
2COVID-19
12/2021 - 01/2021
2Peripheral Vascular Diseases (Peripheral Vascular Disease)
01/2019 - 11/2014
2Hemorrhagic Stroke
01/2019 - 07/2011
2Cerebrovascular Disorders (Cerebrovascular Occlusion)
11/2018 - 05/2009
2Hyperlipidemias (Hyperlipidemia)
01/2018 - 04/2003
2Hypoxia (Hypoxemia)
12/2014 - 08/2014
2Dizziness (Lightheadedness)
08/2014 - 02/2014
2Chronic Kidney Failure (Chronic Renal Failure)
05/2008 - 01/2002
1Embolism (Embolus)
10/2022
1Infections
01/2022
1Sepsis (Septicemia)
12/2021
1Critical Illness (Critically Ill)
12/2021
1Chronic Renal Insufficiency
12/2021
1Anemia
12/2021
1Intracranial Hemorrhages (Intracranial Hemorrhage)
10/2021
1Pneumonia (Pneumonitis)
01/2021
1Chronic Obstructive Pulmonary Disease (COPD)
01/2021
1Dyspnea (Shortness of Breath)
01/2021
1Symptom Flare Up
10/2020
1Sleep Apnea Syndromes (Sleep Apnea)
01/2020
1Cardiac Sudden Death (Sudden Cardiac Arrest)
01/2019
1Hypertriglyceridemia
12/2018

Drug/Important Bio-Agent (IBA)

26TicagrelorIBA
01/2022 - 06/2015
22Clopidogrel (Plavix)FDA Link
01/2022 - 02/2008
13RivaroxabanIBA
10/2022 - 01/2016
12Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
10/2021 - 02/2006
8Cilostazol (Pletal)FDA LinkGeneric
06/2012 - 01/2002
7AnticoagulantsIBA
01/2021 - 01/2003
7omega-Chloroacetophenone (Mace)IBA
01/2021 - 01/2017
7Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
05/2020 - 09/2003
6Pharmaceutical PreparationsIBA
10/2022 - 01/2003
6LDL CholesterolIBA
01/2021 - 01/2002
5Oxygen (Dioxygen)IBA
12/2021 - 09/2004
5CholesterolIBA
11/2018 - 04/2003
4Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
12/2021 - 12/2002
4LipidsIBA
01/2021 - 04/2006
4Carnitine (L-Carnitine)FDA LinkGeneric
02/2013 - 11/2004
3Hemoglobins (Hemoglobin)IBA
12/2021 - 01/2002
3fibrin fragment D (D-dimer)IBA
12/2021 - 01/2016
3oxidized low density lipoproteinIBA
01/2021 - 01/2018
3Biomarkers (Surrogate Marker)IBA
12/2018 - 11/2007
3Phosphodiesterase InhibitorsIBA
02/2012 - 12/2006
3ProstaglandinsIBA
02/2008 - 09/2004
2Triglycerides (Triacylglycerol)IBA
12/2018 - 07/2013
2HDL CholesterolIBA
12/2018 - 07/2013
2Antihypertensive Agents (Antihypertensives)IBA
06/2016 - 08/2007
2Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
05/2015 - 08/2007
2Pain-FreeIBA
07/2013 - 09/2003
2Epoprostenol (Prostacyclin)FDA LinkGeneric
02/2008 - 05/2003
2Type 3 Cyclic Nucleotide PhosphodiesterasesIBA
02/2008 - 12/2002
2CreatinineIBA
08/2007 - 01/2002
2Alprostadil (Muse)FDA LinkGeneric
05/2007 - 04/2006
2EcraprostIBA
05/2007 - 04/2006
1Enoxaparin (Lovenox)FDA LinkGeneric
10/2022
1Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
12/2021
1Paclitaxel (Taxol)FDA LinkGeneric
11/2021
1dicarboxydine (DCD)IBA
11/2021
1Cytochrome P-450 CYP2C19IBA
11/2020
1CytokinesIBA
10/2019
1CanagliflozinIBA
01/2019
1PPAR alphaIBA
12/2018

Therapy/Procedure

36Therapeutics
10/2021 - 01/2002
29Surgical Amputation (Amputations)
01/2022 - 07/2002
3Secondary Prevention
01/2022 - 05/2009
3Percutaneous Coronary Intervention
01/2019 - 06/2017
2Exercise Therapy (Therapy, Exercise)
02/2021 - 01/2002
2Stents
01/2020 - 01/2019
2Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2019 - 12/2018
2Limb Salvage
01/2018 - 03/2003
2Cell- and Tissue-Based Therapy (Cell Therapy)
04/2017 - 11/2014
2Glycemic Control
01/2013 - 01/2002
2Renal Dialysis (Hemodialysis)
09/2002 - 01/2002
1Endovascular Procedures
10/2019
1Aftercare (After-Treatment)
12/2018